Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.2K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.2K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

6.8K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.8K
Feedback Inhibition00:46

Feedback Inhibition

54.0K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
54.0K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.5K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.5K
Feedback Loops01:01

Feedback Loops

57.6K
In most cases, excessive hormone production is prevented by negative feedback—a loop that starts with a stimulus inducing the release of a particular substance, like a hormone, to maintain a certain level before triggering a signal that results in a decrease in further release of the hormone.
57.6K
Contact-dependent Signaling01:19

Contact-dependent Signaling

44.7K
Contact-dependent signaling, as the name suggests, requires that communicating cells be in direct contact with each other. This is achieved either through receptor-ligand interactions or by specialized cytoplasmic channels that allow the flow of small molecules between cells. In animal cells, channels called gap junctions facilitate contact-dependent signaling in certain tissues, whereas, plasmodesmata perform a similar function in plants.
Gap Junctions
In animal cells, gap junctions are formed...
44.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient Engagement With an Electronic Patient-Reported Outcomes Tool Evaluating Hospital Discharge Readiness After Cancer Surgery.

JCO oncology practice·2026
Same author

Developing a Novel Values Elicitation Measure for Clinical Use in Older Adults with Hematologic Malignancies: Values-HM.

MDM policy & practice·2026
Same author

Benefits of Electronic Symptom Monitoring During Cancer Treatment by Age, Sex, Race, and Education (Alliance AFT-39).

JCO oncology practice·2026
Same author

Remote Therapeutic Monitoring and Infection-Related Health Care Resource Utilization in Patients With Hematologic Malignancies.

JCO oncology practice·2026
Same author

Supporting Reimbursement for Electronic Patient-Reported Outcomes in Clinical Cancer Care Using Current Procedural Terminology Codes for Remote Therapeutic Monitoring.

JCO oncology practice·2026
Same author

ATOMIC Energy - Biomarker-Bespoke Adjuvant Therapy for Colon Cancer.

The New England journal of medicine·2026
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Related Experiment Video

Updated: Jul 14, 2025

Methods to Test Endocrine Disruption in Drosophila melanogaster
09:43

Methods to Test Endocrine Disruption in Drosophila melanogaster

Published on: July 3, 2019

9.8K

Reply to F. Dossa et al

Ethan Basch1, Amylou Dueck1, Martin Weiser1

  • 1Ethan Basch, MD, Division of Oncology, University of North Carolina, Chapel Hill, NC; Amylou Dueck, PhD, Department of Quantitative Health Sciences, Mayo Clinic School of Graduate Medical Education, Scottsdale, AZ; Martin Weiser, MD, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; and Deborah Schrag, MD, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|October 10, 2023
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Analysis of Oxidative Stress in Zebrafish Embryos
11:05

Analysis of Oxidative Stress in Zebrafish Embryos

Published on: July 7, 2014

37.3K
Straightforward Assay for Quantification of Social Avoidance in Drosophila melanogaster
08:08

Straightforward Assay for Quantification of Social Avoidance in Drosophila melanogaster

Published on: December 13, 2014

11.3K

Related Experiment Videos

Last Updated: Jul 14, 2025

Methods to Test Endocrine Disruption in Drosophila melanogaster
09:43

Methods to Test Endocrine Disruption in Drosophila melanogaster

Published on: July 3, 2019

9.8K
Analysis of Oxidative Stress in Zebrafish Embryos
11:05

Analysis of Oxidative Stress in Zebrafish Embryos

Published on: July 7, 2014

37.3K
Straightforward Assay for Quantification of Social Avoidance in Drosophila melanogaster
08:08

Straightforward Assay for Quantification of Social Avoidance in Drosophila melanogaster

Published on: December 13, 2014

11.3K